- Home
- OPHC vs PRLD Comparison
OPHC vs PRLD Comparison
Compare OPHC & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPHC
- PRLD
- Stock Information
- Founded
- OPHC 2000
- PRLD 2016
- Country
- OPHC United States
- PRLD United States
- Employees
- OPHC N/A
- PRLD N/A
- Industry
- OPHC Major Banks
- PRLD Medicinal Chemicals and Botanical Products
- Sector
- OPHC Finance
- PRLD Health Care
- Exchange
- OPHC Nasdaq
- PRLD Nasdaq
- Market Cap
- OPHC 49.0M
- PRLD 53.4M
- IPO Year
- OPHC N/A
- PRLD 2020
- Fundamental
- Price
- OPHC $4.94
- PRLD $0.93
- Analyst Decision
- OPHC Hold
- PRLD Buy
- Analyst Count
- OPHC 1
- PRLD 3
- Target Price
- OPHC $5.25
- PRLD $4.33
- AVG Volume (30 Days)
- OPHC 80.4K
- PRLD 450.1K
- Earning Date
- OPHC 11-08-2024
- PRLD 11-06-2024
- Dividend Yield
- OPHC N/A
- PRLD N/A
- EPS Growth
- OPHC 78.77
- PRLD N/A
- EPS
- OPHC 1.32
- PRLD N/A
- Revenue
- OPHC $34,509,000.00
- PRLD $3,000,000.00
- Revenue This Year
- OPHC N/A
- PRLD N/A
- Revenue Next Year
- OPHC N/A
- PRLD N/A
- P/E Ratio
- OPHC $3.64
- PRLD N/A
- Revenue Growth
- OPHC 66.69
- PRLD N/A
- 52 Week Low
- OPHC $3.74
- PRLD $0.80
- 52 Week High
- OPHC $5.90
- PRLD $6.80
- Technical
- Relative Strength Index (RSI)
- OPHC 53.11
- PRLD 34.45
- Support Level
- OPHC $4.84
- PRLD $0.80
- Resistance Level
- OPHC $5.04
- PRLD $0.95
- Average True Range (ATR)
- OPHC 0.11
- PRLD 0.09
- MACD
- OPHC -0.01
- PRLD 0.02
- Stochastic Oscillator
- OPHC 60.47
- PRLD 22.04
About OPHC OptimumBank Holdings Inc.
OptimumBank Holdings Inc serves as a bank holding company for OptimumBank. The Bank provides a range of community banking services to individuals and corporate customers. Its services include demand interest-bearing and non-interest-bearing accounts, negotiable order of withdrawal account, money market deposit accounts, debit cards, and automated teller machines.
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical-stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.